Clinical trials: Post-PV MF
Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
This study evaluates either KRT-232 or TL-895 in treatment naïve patients with myelofibrosis (MF) The study will be conducted in 2 stages.
- Conditions
- Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
- Trial name
- NCT04878003
- Testing
- KRT-232, TL-895
- Where
- 29 sites in United States, Belarus and 7 more
- Volunteers
- 52 people
- Sponsor
- Kartos Therapeutics, Inc.
Idiopathic Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis
Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis
This study will assess safety as well as establish a Recommended Phase II dose of the combination of panobinostat and ruxolitinib in patients with or without the JAK2V617F mutation who have been diagnosed with primary…
- Conditions
- Idiopathic Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia-Vera Myelofibrosis
- Trial name
- NCT01433445
- Testing
- panobinostat, ruxolitinib
- Where
- 10 sites in France, Germany and 3 more
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals
Primary Myelofibrosis, Myelofibrosis
Study of Select Combinations in Adults With Myelofibrosis
The purpose of this study is to investigate the safety, pharmacokinetics (PK) and preliminary efficacy of both the combination of MBG453 and NIS793 with or without decitabine or spartalizumab as well as single agent MBG453 and/or…
- Conditions
- Primary Myelofibrosis, Myelofibrosis, PMF, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT04283526
- Testing
- MBG453, NIS793, Spartalizumab
- Sponsor
- Novartis Pharmaceuticals
Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera
Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis
The goal of this clinical trial is to learn which of three different doses of Flonoltinib Maleate taken by mouth daily works best to treat adult patients with myelofibrosis in whom the most common approved therapy has failed to…
- Conditions
- Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential Thrombocythemia, Myelofibrosis With High Molecular Risk Mutations
- Trial name
- FM-MF-02 (NCT07750574)
- Testing
- Flonoltinib Maleate orally
- Volunteers
- 105 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV)
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
This study is to determine the efficacy of momelotinib (MMB) versus best available therapy (BAT) in anemic or thrombocytopenic adults with primary myelofibrosis (PMF), or post-polycythemia vera or post-essential thrombocythemia…
- Conditions
- Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Trial name
- Simplify 2 (NCT02101268)
- Testing
- Momelotinib, Best Available Therapy (BAT)
- Where
- 48 sites in United States, Canada and 6 more
- Volunteers
- 156 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
The purpose of this study was to evaluate the effect of an alternative dosing strategy of ruxolitinib in subjects with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) and post essential…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT01445769
- Testing
- Ruxolitinib
- Where
- 21 sites in United States
- Volunteers
- 45 people
- Sponsor
- Incyte Corporation
Primary Myelofibrosis, MPN-associated Myelofibrosis
Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence
The objective of this study is to determine whether pomalidomide is safe and effective in reversing red blood cell (RBC)-transfusion-dependence in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis (global…
- Trial name
- RESUME (NCT01178281)
- Testing
- Pomalidomide 0.5 mg, Pomalidomide
- Where
- 87 sites in United States, Australia and 14 more
- Volunteers
- 267 people
- Sponsor
- Celgene
MPN (Myeloproliferative Neoplasms)
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
To evaluate the effects of treatment with ruxolitinib (INCB018424) on spleen volume, symptoms and potential side effects in participants with PMF, PPV-MF and PET-MF who have platelet counts of 50 x 10^9/L to 100 x 10^9/L.
- Trial name
- NCT01348490
- Testing
- Ruxolitinib
- Where
- 38 sites in United States
- Volunteers
- 66 people
- Sponsor
- Incyte Corporation
Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF
Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF
The objective of this study was to determine the efficacy of INC424 as assessed by reduction in spleen volume in patients with primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF.
- Conditions
- Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Post-Essential Thrombocythemia (ET) MF
- Trial name
- NCT01392443
- Testing
- Ruxolitinib
- Where
- 26 sites in China, Japan and 2 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Polycythemia Vera
A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera
This is a two-part, multicenter, open label, non-randomized, phase Ib/II study to assess the safety and tolerability, Maximum Tolerated Dose and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia…
- Trial name
- NCT01901432
- Testing
- Givinostat
- Where
- 25 sites in France, Germany and 3 more
- Volunteers
- 48 people
- Sponsor
- Italfarmaco
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
This was an open-label, randomized, dose-finding study in patients with primary or secondary MF (Dynamic International Prognostic Scoring System [DIPSS] risk score of Intermediate-1 to High-Risk) who were previously treated with…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post- Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT04884191
- Testing
- Pacritinib
- Where
- 62 sites in United States, France and 6 more
- Volunteers
- 165 people
- Sponsor
- CTI BioPharma
Myelofibrosis
Actuate 1901: 9-ING-41 in Myelofibrosis
9-ING-41 has anti-cancer clinical activity while not causing myelosuppression, and has both pre-clinical anti-fibrotic activity and activity against myelofibrosis.
- Trial name
- NCT04218071
- Testing
- Ruxolitinib, 9-ING-41
- Where
- 9 sites in United States
- Volunteers
- 17 people
- Sponsor
- Actuate Therapeutics Inc.
Hematopoietic Neoplasm
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
Primary Objective: To evaluate the efficacy of daily oral doses of 400 mg or 500 mg of SAR302503 (Investigational Medicinal Product, IMP) compared to placebo in the reduction of spleen volume as determined by magnetic resonance…
- Trial name
- JAKARTA (NCT01437787)
- Testing
- SAR302503
- Where
- 101 sites in United States, Australia and 23 more
- Volunteers
- 289 people
- Sponsor
- Bristol-Myers Squibb
Myelofibrosis, Primary Myelofibrosis
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis.
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
- Trial name
- NCT05280509
- Testing
- TL-895, Ruxolitinib
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 70 people
- Sponsor
- Telios Pharma, Inc.
Myelofibrosis, Polycythemia Vera
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.
- Conditions
- Myelofibrosis, Polycythemia Vera, Thrombocythemia
- Trial name
- NCT04629508
- Testing
- itacitinib
- Where
- 21 sites in United States, Austria and 5 more
- Volunteers
- 4 people
- Sponsor
- Incyte Corporation
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis
A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis
The purpose of this study is to assess the real-world safety of fedratinib for the treatment of adult participants with primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), or post essential…
- Conditions
- Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- NCT06073847
- Testing
- Fedratinib
- Where
- 3 sites in South Korea
- Volunteers
- 137 people
- Sponsor
- Bristol-Myers Squibb
Myelofibrosis
A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis
The purpose of this study is to evaluate the safety and tolerability of orally administered TG101348 in patients with myelofibrosis.
- Trial name
- NCT00631462
- Testing
- TG101348
- Where
- 6 sites in United States
- Volunteers
- 59 people
- Sponsor
- TargeGen
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
This open-label study is to determine the long-term safety and tolerability of momelotinib in previously enrolled study participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF)…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Polycythemia Vera
- Trial name
- NCT02124746
- Testing
- Momelotinib
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 87 people
- Sponsor
- Sierra Oncology LLC - a GSK company